ProShare Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

ProShare Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$204K	Sell	13,710 -657	-5%	-$14.6K	﹤0.01%	1568
2025 Q4	$359K	Buy	14,367 +1,740	+14%	+$31K	﹤0.01%	1343
2025 Q3	$124K	Sell	12,627 -2,139	-14%	-$12.8K	﹤0.01%	1807
2025 Q2	$62.9K	Buy	14,766 +2,569	+21%	+$11.5K	﹤0.01%	1965
2025 Q1	$45.9K	Sell	12,197 -2,029	-14%	-$10.2K	﹤0.01%	1962
2024 Q4	$82.9K	Buy	14,226 +3,298	+30%	+$32.9K	﹤0.01%	2105
2024 Q3	$130K	Buy	+10,928	New	+$140K	﹤0.01%	1841
2022 Q1	–	Sell	-11,173	Closed	-$105K	–	2270
2021 Q4	$105K	Buy	+11,173	New	+$231K	﹤0.01%	2197

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

ProShare Advisors's OLMA Position: Q1 2026 in Review

ProShare Advisors reduced its Olema Pharmaceuticals (OLMA) stake by 4.6% in Q1 2026, selling an estimated $14.6K and leaving 13,710 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

ProShare Advisors first reported a position in OLMA in Q4 2021 and has held it in 8 quarters since. The position peaked at $359K in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

ProShare Advisors held 13,710 shares of Olema Pharmaceuticals worth $204K as of Q1 2026.
ProShare Advisors sold 657 Olema Pharmaceuticals shares in Q1 2026, an estimated $14.6K.
Olema Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1568 holding.
ProShare Advisors first reported a position in Olema Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
ProShare Advisors's Olema Pharmaceuticals position peaked at $359K in Q4 2025.
195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.